Increased understanding of the role of metabolic pathways in the biology of primary bone cancers has led to the identification of potential therapeutic targets, such as 3-phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the biosynthesis of serine from glucose. Here, PHGDH is linked to bone cancer.